Medical Developments International Net Margin
The Net Profit Margin of Medical Developments International (MVP.AX) as of Jul 26, 2026 is 0.24 %. In the previous year, Net Profit Margin was -123.66 % — a change of -100.19% (higher).
Get this data via API
Financial Data API
Net Margin
0.24 %
YoY
-100.19%
Last updated:
Net Profit Margin of Medical Developments International is 2026 0.24 % . Net Profit Margin of Medical Developments International was 2025 -123.66 % . It decreases by -100.19% higher compared to the previous year.
For Medical Developments International, the net margin of 0.2% is up versus -49.6% a few years ago.
Access this data via the Eulerpool API
Medical Developments International Stock analysis
What does Medical Developments International do? Medical Developments International Ltd is an Australian company specializing in the development and production of medical devices and products. The company was founded in 1971 by renowned researcher and entrepreneur Mark Sullivan and has since received numerous awards and accolades. The company's business model is based on the manufacture of emergency medical devices and products of the highest quality and effectiveness. It has three main business segments: Pharmaceuticals, Medical devices, and Animal health. Medical Developments International is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Medical Developments International stock
Net Profit Margin of Medical Developments International is 0.24 % in 2026.
Access this data via the Eulerpool API
Margins — Medical Developments International
All Key Metrics — Medical Developments International
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth